Telomir Pharmaceuticals, Inc. (TELO) Income Statement
TELO FY2025 at a glance
Fiscal year ended September 30, 2025 · U.S. dollarsTELO revenue and net income
TELO growth rates
to FY2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
TELO quarterly EPS vs estimates
Telomir Pharmaceuticals beat the analyst EPS estimate in 2 of the last 4 quarters. Next report: November 9, 2026.
TELO income statement
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | — | $3.9M | — | — |
| Gross profit | — | — | −$3.9M | — | — |
| Research & development | $2.4M | $2.2M | $1.6M | $833,206 | $126,492 |
| Sales, general & admin | $8.1M | $9.6M | $600,192 | $20,941 | $11,639 |
| Total operating expenses | $10.5M | $12.2M | $3.9M | $854,147 | $138,131 |
| Operating income | −$10.5M | −$12.2M | −$3.9M | −$854,147 | −$138,131 |
| Interest income | $125,644 | $48,000 | $0 | — | — |
| Interest expense | $0 | $4.3M | $1.6M | $0 | — |
| Income before taxes | −$10.4M | −$16.5M | −$13.1M | −$854,147 | −$138,131 |
| Income taxes | — | −$16.5M | −$2.3M | −$854,144 | −$138,132 |
| Net income | −$10.4M | −$16.5M | −$13.1M | −$854,147 | −$138,131 |
| EBITDA | −$10.4M | −$7.9M | −$11.4M | −$854,147 | −$138,131 |
| EPS (diluted) | −$0.37 | −$0.48 | −$0.44 | −$0.03 | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $18.8M | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | — | — | — | — | — | $9.4M | $6.0M | $1.5M | $1.9M | — | — |
| Gross profit | — | — | — | — | — | — | $9.4M | −$6.0M | −$1.5M | −$1.9M | — | — |
| Research & development | $444,674 | $467,797 | $1.3M | $759,525 | $42,839 | $336,996 | $269,083 | $627,434 | $594,801 | $804,023 | $203,784 | $262,562 |
| Sales, general & admin | $1.3M | $573,539 | $838,472 | $386,951 | $5.0M | $1.9M | $2.6M | $5.4M | $879,695 | $741,541 | $395,290 | $691,591 |
| Total operating expenses | $1.8M | $1.0M | $2.1M | $1.1M | $5.1M | $2.2M | $2.9M | $6.0M | $1.5M | $1.9M | $1.1M | $954,153 |
| Operating income | −$1.8M | −$1.0M | −$2.1M | −$1.1M | −$5.1M | −$2.2M | −$2.9M | −$6.0M | −$1.5M | −$1.9M | −$1.1M | −$954,153 |
| Interest income | $46,176 | $51,644 | $72,100 | $44,182 | $1,362 | $8,000 | $7,061 | $15,445 | $25,493 | — | — | $0 |
| Interest expense | $3,028 | $1,255 | $1,388 | $2,730 | $1,342 | $7,954 | $1 | $0 | $0 | $4.3M | $761,824 | $757,173 |
| Income before taxes | −$1.7M | −$990,947 | −$2.1M | −$1.1M | −$5.1M | −$2.2M | −$2.9M | −$6.0M | −$1.4M | −$6.3M | −$9.3M | −$1.7M |
| Income taxes | — | — | — | — | — | — | — | — | — | −$1.9M | −$1.1M | −$954,153 |
| Net income | −$1.7M | −$990,947 | −$2.1M | −$1.1M | −$5.1M | −$2.2M | −$2.9M | −$6.0M | −$1.4M | −$6.3M | −$9.3M | −$1.7M |
| EBITDA | −$1.7M | −$989,692 | −$2.1M | −$1.1M | −$5.1M | −$2.2M | −$2.9M | −$6.0M | −$1.4M | −$1.9M | −$8.6M | −$954,153 |
| EPS (diluted) | −$0.79 | −$0.03 | −$0.06 | −$0.03 | −$0.17 | −$0.07 | −$0.10 | −$0.20 | −$0.05 | −$0.23 | — | — |
| Gross margin | — | — | — | — | — | — | 50.0% | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | −15.5% | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | −15.4% | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in TELO's financial statements (latest annual report filed March 17, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
TELO financial results
Telomir Pharmaceuticals reported no revenue in fiscal year 2025 (ended September 30, 2025). It had a net loss of $10.4 million. Diluted earnings per share came to −$0.37.
See the TELO stock overview for the latest quote and news, or the TELO chart for price history and technical indicators.
TELO income statement FAQ
Does Telomir Pharmaceuticals have revenue?
Telomir Pharmaceuticals reported no revenue for fiscal year 2025, which ended on September 30, 2025.
Is Telomir Pharmaceuticals profitable?
No. Telomir Pharmaceuticals reported a net loss of $10.4 million in fiscal 2025.
How much does Telomir Pharmaceuticals spend on research and development?
Telomir Pharmaceuticals spent $2.4 million on research and development in fiscal 2025.
What are Telomir Pharmaceuticals's earnings per share?
Telomir Pharmaceuticals earned $-0.37 per diluted share in fiscal 2025, compared with $-0.48 a year earlier.
When will Telomir Pharmaceuticals report its next earnings?
Telomir Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 9, 2026.
When does Telomir Pharmaceuticals's fiscal year end?
Telomir Pharmaceuticals's fiscal year ends in September. The latest annual report covers the year ended September 30, 2025 and was filed on March 17, 2026.